Oncolin Therapeutics, Inc. (OCOL.OB) is a biopharmaceutical company working toward developing drugs that will interfere with cancer tumor development. Oncolin is also focused on discovering, developing, and commercializing anti-cancer therapies, and has a lead brain cancer drug in preclinical development. The company extends their research with many oncology research programs funded by federal grants.
Oncolin’s brain cancer drug is licensed from the MD Anderson Cancer Center. The company is determined to develop this drug, and anticipates filing an Investigational New Drug application with the FDA. In preclinical testing, Oncolin’s lead drug revealed its ability to extend the life of animals that have implanted human tumors in their brains. The testing has also revealed results equal to a leading brain cancer drug.
Oncolin is also involved in three active research programs, all funded by peer-reviewed national Institutes of Health grants. The company is in negotiation with the Pharmaceutical Research Institute of Warsaw, Poland and has already obtained worldwide rights to a patent for the use and composition of Genistein analogs for cancer treatment. In addition, Oncolin has the exclusive option to license through The University of Texas M.D. Anderson.
Let us hear your thoughts: Oncolin Therapeutics, Inc. Message Board